Access to this article is restricted until 12 months after publication by request of the publisher.. Restriction lift date: 2017-08-23
Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients
Stam-Slob, Manon C.
Visseren, Frank L. J.
Jukema, J. Wouter
van der Graaf, Yolanda
Poulter, Neil R.
Macfarlane, Peter W.
Kearney, Patricia M.
de Craen, Anton J. M.
Springer International Publishing
Objective: To estimate the absolute treatment effect of statin therapy on major adverse cardiovascular events (MACE; myocardial infarction, stroke and vascular death) for the individual patient aged C70 years. Methods: Prediction models for MACE were derived in patients aged C70 years with (n = 2550) and without (n = 3253) vascular disease from the ‘‘PROspective Study of Pravastatin in Elderly at Risk’’ (PROSPER) trial and validated in the ‘‘Secondary Manifestations of ARTerial disease’’ (SMART) cohort study (n = 1442) and the ‘‘Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm’’ (ASCOT-LLA) trial (n = 1893), respectively, using competing risk analysis. Prespecified predictors were various clinical characteristics including statin treatment. Individual absolute risk reductions (ARRs) for MACE in 5 and 10 years were estimated by subtracting ontreatment from off-treatment risk. Results: Individual ARRs were higher in elderly patients with vascular disease [5-year ARRs: median 5.1 %, interquartile range (IQR) 4.0–6.2 %, 10-year ARRs: median 7.8 %, IQR 6.8–8.6 %] than in patients without vascular disease (5-year ARRs: median 1.7 %, IQR 1.3–2.1 %, 10-year ARRs: 2.9 %, IQR 2.3–3.6 %). Ninetyeight percent of patients with vascular disease had a 5-year ARR C2.0 %, compared to 31 % of patients without vascular disease. Conclusions: With a multivariable prediction model the absolute treatment effect of a statin on MACE for individual elderly patients with and without vascular disease can be quantified. Because of high ARRs, treating all patients is more beneficial than prediction-based treatment for secondary prevention of MACE. For primary prevention of MACE, the prediction model can be used to identify those patients who benefit meaningfully from statin therapy.
Elderly , Statin , Absolute treatment effect , Vascular disease
Stam-Slob, M.C., Visseren, F.L., Jukema, J.W., van der Graaf, Y., Poulter, N.R., Gupta, A., Sattar, N., Macfarlane, P.W., Kearney, P.M., de Craen, A.J. and Trompet, S. (2016)'Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients', Clinical Research in Cardiology, pp.1-11. doi: 10.1007/s00392-016-1023-8
© 2016, the Authors. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.